Bank Pictet & Cie Europe AG Cuts Stock Holdings in Boston Scientific Corporation $BSX

Bank Pictet & Cie Europe AG trimmed its stake in Boston Scientific Corporation (NYSE:BSX) by 4.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 157,936 shares of the medical equipment provider’s stock after selling 6,718 shares during the period. Bank Pictet & Cie Europe AG’s holdings in Boston Scientific were worth $15,419,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. GAMMA Investing LLC lifted its position in Boston Scientific by 15.4% in the 2nd quarter. GAMMA Investing LLC now owns 29,486 shares of the medical equipment provider’s stock worth $3,167,000 after buying an additional 3,932 shares during the last quarter. State Street Corp raised its stake in shares of Boston Scientific by 1.1% during the second quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock worth $7,002,258,000 after acquiring an additional 713,379 shares in the last quarter. MRA Advisory Group bought a new stake in shares of Boston Scientific in the 2nd quarter worth approximately $273,000. Bank of New Hampshire lifted its holdings in shares of Boston Scientific by 552.0% in the 2nd quarter. Bank of New Hampshire now owns 19,724 shares of the medical equipment provider’s stock worth $2,119,000 after acquiring an additional 16,699 shares during the last quarter. Finally, New England Research & Management Inc. purchased a new stake in shares of Boston Scientific in the 2nd quarter valued at $1,133,000. 89.07% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the transaction, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,396,580. This represents a 42.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ellen M. Zane sold 12,891 shares of the firm’s stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the completion of the sale, the director directly owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. This represents a 34.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 93,095 shares of company stock valued at $9,305,450. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Trading Down 0.7%

BSX opened at $95.29 on Friday. The business has a 50 day simple moving average of $98.05 and a two-hundred day simple moving average of $100.97. The firm has a market capitalization of $141.26 billion, a price-to-earnings ratio of 50.96, a PEG ratio of 1.92 and a beta of 0.67. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96. Boston Scientific Corporation has a one year low of $85.98 and a one year high of $109.50.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. The firm had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The business’s quarterly revenue was up 20.3% compared to the same quarter last year. During the same period last year, the company earned $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Wall Street Analysts Forecast Growth

BSX has been the topic of a number of analyst reports. UBS Group reiterated a “buy” rating on shares of Boston Scientific in a research report on Wednesday, December 17th. Wells Fargo & Company lifted their price objective on Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. Evercore ISI reissued an “outperform” rating on shares of Boston Scientific in a research note on Wednesday, October 22nd. Cowen restated a “buy” rating on shares of Boston Scientific in a report on Thursday, December 11th. Finally, Canaccord Genuity Group reduced their price target on Boston Scientific from $132.00 to $131.00 and set a “buy” rating on the stock in a research report on Wednesday, December 17th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Boston Scientific currently has a consensus rating of “Buy” and a consensus price target of $124.85.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.